Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

– Topline results expected in November 2022 BALTIMORE, April 21, 2021 — AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s…

Richard Mohs, AgeneBio VP for Clinical Development, Presents at 2021 NIH Alzheimer Disease Summit

AGB101 to Slow the Progression of MCI in Alzheimer’s Disease

Sharon Rosenzweig-Lipson, AgeneBio VP of Research and Development, Presents at the 9th Annual Neurodegeneration Drug Development Summit

AgeneBio Featured at Longevity Innovations and Neurodegeneration Company Showcase

HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101

AgeneBio Presents at Biotech Showcase

HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101

Presentation at Alzheimer’s Association International Conference (AAIC) Read more

Darryle Schoepp, Ph.D. joins the AgeneBio Board of Directors

AgeneBio, Inc. panel participation at American College of Neuropsychopharmacology meeting (ACNP)

Bridging the Gap From Research Discovery to a Bonafide Neurotherapeutic: Sponsored by NIH Blueprint Neurotherapeutic Program

Sharon Rosenzweig-Lipson, AgeneBio VP of R&D. presents at Clinical Trials in Alzheimer’s Disease conference (CTAD)

Founder & CEO Dr. Michela Gallagher Featured in Alzheimer’s Drug Discovery Foundation Video

Learn more about our important work in this video.